Biotech: What’s Next For Gilead, Glaxo, and Merck HIV Treatments

The Conference on Retroviruses and Opportunistic Infections (CROI) Annual Meeting took place last week, and while this meeting is one of the most important for HIV treatment data, it's closed to investors and non-clinicians. As such, Leerink's Geoffrey Porges and Bradley Canino hosted a call with two specialists in HIV treatment, to discuss their impressions of the meeting.